Ionis grants ProQR rights to QR-1123

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted ProQR Therapeutics N.V. (NASDAQ:PRQR) exclusive, worldwide rights to QR-1123 (formerly IONS-RHO-2.5Rx) along with relevant IP.

Ionis received $2.5 million in ProQR shares upfront. The partners said the shares were priced at $22.23, which represents a 26% premium to ProQR's close of $17.66 on Oct. 26, before the deal was announced. Ionis is eligible for milestones, plus royalties of 20%. The milestones are to be paid in cash or stock at ProQR's discretion...